Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533450 | 1.00 | OPRD1 (0.36) | OPRD1CYP51A1RENMMEHRH3 | |
| SCHEMBL3361699 | 0.81 | CYP51A1 (0.46) | OPRD1CYP51A1RENMMEHRH3 | |
| SCHEMBL3047893 | 0.76 | OPRD1 (0.49) | OPRD1CYP51A1HRH2HRH1 | |
| SCHEMBL27800005 | 0.76 | OPRD1 (0.49) | OPRD1CYP51A1HRH2HRH1 | |
| SCHEMBL867917 | 0.75 | GHSR (0.53) | CYP51A1MMEPYGL | |
| SCHEMBL867918 | 0.75 | GHSR (0.53) | CYP51A1MMEPYGL | |
| SCHEMBL868066 | 0.73 | GHSR (0.42) | OPRD1CYP51A1MMEHRH2HRH1 | |
| SCHEMBL868545 | 0.73 | GHSR (0.57) | OPRD1CYP51A1 | |
| SCHEMBL868065 | 0.73 | GHSR (0.42) | OPRD1CYP51A1MMEHRH2HRH1 | |
| SCHEMBL868544 | 0.73 | GHSR (0.57) | OPRD1CYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039457-B2 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087381-A1 | Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues | GHSR, GHRHR, MLNR | OPRD1 57/4885CYP51A1 2293/4885REN 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.